Study of correlation between the NAT2 phenotype and genotype status among Greenlandic Inuit
Open Access
- 2 November 2018
- journal article
- research article
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 17, 1043-1053
Abstract
N-acetyltransferase 2 (NAT2) is the main enzyme metabolizing isoniazid and genotype-based treatment has been studied for years without becoming common practice. To investigate whether genotype-based isoniazid treatment is feasible in Greenland, we sequenced the coding sequence of NAT2 and determined the NAT2 enzyme-activity by caffeine test. No additional genetic variants were identified in the coding sequence of NAT2, so that genotype status in 260 study participants could be assessed by a well-established 7-SNP panel. Studying the enzyme activity by the ratio of the two caffeine metabolites AFMU and 1X in 260 participants showed a high rate of slow phenotypes with intermediate or rapid genotype. These misclassifications were mainly observed in urine samples with pH3, we observed a moderate level of discrepancies (19 of the 116 individuals with intermediate or rapid genotype status having a slow phenotype). Further investigation showed that drinking coffee and not tea or cola was the most important factor for high levels of both metabolites. The concordance between phenotype and genotype status with regard to slow metabolism supported the recommendation of lower isoniazid doses in individuals with slow genotype status in order to avoid liver injury, a frequent side effect. The phenotypical variation observed for individuals with intermediate or rapid genotype status warrants further research before increased dosing of isoniazid can be recommended.Keywords
This publication has 31 references indexed in Scilit:
- NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapyEuropean Journal of Clinical Pharmacology, 2012
- The Differential Effect of NAT2 Variant Alleles Permits Refinement in Phenotype Inference and Identifies a Very Slow Acetylation GenotypePLOS ONE, 2012
- Accuracy of Various Human NAT2 SNP Genotyping Panels to Infer Rapid, Intermediate and Slow Acetylator PhenotypesPharmacogenomics, 2011
- Arylamine N-Acetyltransferase 2 (NAT2) Genetic Diversity and Traditional Subsistence: A Worldwide Population SurveyPLOS ONE, 2011
- A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility lociNature Genetics, 2010
- The Dietary Quality Score: validation and association with cardiovascular risk factors: the Inter99 studyEuropean Journal of Clinical Nutrition, 2006
- Should We Use N -Acetyltransferase Type 2 Genotyping To Personalize Isoniazid Doses?Antimicrobial Agents and Chemotherapy, 2005
- novoSNP, a novel computational tool for sequence variation discoveryGenome Research, 2005
- A Comparison of Bayesian Methods for Haplotype Reconstruction from Population Genotype DataThe American Journal of Human Genetics, 2003
- Human Arylamine N -Acetyltransferase Genes: Isolation, Chromosomal Localization, and Functional ExpressionDNA and Cell Biology, 1990